Overestimation of tumor mutational burden (TMB) using algorithms compared to germline subtraction [May 26, 2019] @kaushalpar et al. @AMansfieldMD #ASCO19 Abstract 2621 ascopubs.org/doi/abs/10.1... #PrecisionMedicine #ImmunoOnc #geneticcounselors @MayoCancerCare @TempusLabs
Ok, I’m standing in the line at @Starbucks at SAT. #TNBC #MBC at #SABCS19 - not much. #IMpassion130 was reported at #ASCO19. Slides here ⬇️ 1/2 (or maybe 3?) #oncoalert #bcsm
Young-PEARL study (1st presented at #ASCO19) showed CDK4/6 + AI (+ ovarian suppression as these were young women) inhibitors were superior to capecitabine #SABCS19 #oncoalert #bcsm #ERpos
While @drdonsdizon is clearly the best dressed man at all the conferences, I think @DrSGraff wins for best dressed woman! #FashionPlate #ASCO19
This brilliant piece by @ihatebreastcanc
is a must read for every one in @ASCO leadership @CliffordHudis. Heck, it’s a must read for everyone. #ASCO19
ASCO Voices: Putting the ME in Metastatic Breast Cancer | LinkedIn...
Male questioners will you please call female presenters by their honorifics, as you do male? #ASCO19 #SexismIsAliveAndWell
Report of MONALESSA7 by Dr Sara Hurvitz shows improved OS in premenopausal women on endocrine therapy + ovarian suppression + ribociclib #ASCO19
Dr Sara Tolaney “it should be SOC to test [metastatic] patients for PD-L1” #ASCO19
Dr Peter Schmid presenting on IMpassion 130 - atezolizumab is effective in the PDL1+ mTNBC subpopulation #ASCO19
Dr Jeff Peppercorn speaking on RTT: all patients should have a right to proven cancer therapy. And part of that, IMO, is that all humans have a right to quality health care. #ASCO19
Dr Kelly Hunt speaking about breast surgery in the de novo #MBC population: it seems to be of benefit #ASCO19
I feel like a proud mom: here’s our girl Kelli Davis @Smellimd82 on the podium at #ASCO19. She rocked it 👏🏻❤️👏🏻❤️
After the 80° temperatures on Friday it’s been cold rainy chilly and every combination thereof here. Makes it a lot easier to stay at the meeting and not explore Chicago #bcsm #ASCO19
Talking about challenges of a foreign patient coming to US or US patient going overseas for a trial - hell, there are incredible logistical and financial challenges of US patients wanting to participate in a US trial #ASCO19
Hadn’t thought about a trial outside of the US. Trial + vacation (assuming good quality of care). Heck yeah! #ASCO19
Round table convened with all stakeholders (industry, oncs, NCI, FDA, patients, etc) & recommendations generated @BeverlyMoy #ASCO19
Patients should not have to pay to be on a clinical trial (co-pays, travel costs, etc. enjoying this session with @BeverlyMoy #ASCO19
Dr Turner: we can do 100-200 gene somatic testing that is cost effective now. My question stands: why aren’t we doing this yet in every metastatic patient, if not to inform therapy, then to inform the direction of current research? #ASCO19
Dr Turner illustrated how identifying a mismatch repair deficiency in #MBC can make a difference with treatment choice, in the roughly 2% with this. Is this testing now ready for prime time? 2% is low, but effective treatment is surely impactful for them #ASCO19
With results of SOLAR 1, as Dr N Turner reports, testing for PIK3CA may be warranted, and other mutations are being studied #ASCO19
Now up, Dr Nicholas Turner, on somatic (in the tumor itself) mutations. The metastatic tumor is genomically different than the primary #ASCO19
